公开(公告)号：AU2008304192B9

公开(公告)日：2014-08-21

申请号：AU2008304192

申请日：2008-09-26

Applicant: PORTOLA PHARM INC

Inventor： SINHA UMA ,  PHILLIPS DAVID R ,  ANDRE PATRICK ,  LU GENMIN

IPC: A61K39/00

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa.The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

公开(公告)号：NZ583944A

公开(公告)日：2012-06-29

申请号：NZ58394408

申请日：2008-09-26

Applicant: PORTOLA PHARM INC

Inventor： LU GENMIN ,  PHILLIPS DAVID R ,  ANDRE PATRICK ,  SINHA UMA

IPC: A61K39/395 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/715 ,  A61K31/727 ,  A61K38/36 ,  A61K38/48 ,  A61K39/00 ,  A61K47/48 ,  A61P7/02 ,  A61P7/04 ,  C07H21/00 ,  C07K14/00 ,  C07K16/00 ,  C12N5/10 ,  C12N9/64 ,  C12P21/00

Abstract: A factor Xa polypeptide having the amino acid sequence of SEQ ID NO: 10, 11, 12 or 13. The polypeptides have (a) reduced procoagulant activity compared to wild-type factor Xa, (b) is capable of binding to a factor Xa inhibitor and (c) does not assemble into a prothrombinase complex. The polypeptide can be used to reduce bleeding in a subject undergoing anticoagulant therapy with a factor Xa inhibitor.

公开(公告)号：MX2009011843A

公开(公告)日：2010-04-22

申请号：MX2009011843

申请日：2008-05-02

Applicant: PORTOLA PHARM INC

Inventor： PANDEY ANJALI ,  CONLEY PAMELA B ,  ANDRE PATRICK ,  GRETLER DANIEL D ,  HUTCHALEELAHA ATHIWAT ,  PHILLIPS DAVID R ,  WOLIN HUANG ,  SCARBOROUGH ROBERT M

IPC: A61K31/216 ,  A61K31/517 ,  A61P7/02

Abstract: La presente invenci?n proporciona m?todos y composiciones para la inhibici?n r?pida e irreversible de la agregaci?n de plaquetas en los sujetos humanos que los necesitan administrando los compuestos de la f?rmula: (I) solos o en combinaci?n con un segundo agente el cual puede ser aspirina o un agente anti trombol?tico.

公开(公告)号：CA2697583A1

公开(公告)日：2009-04-02

申请号：CA2697583

申请日：2008-09-26

Applicant: PORTOLA PHARM INC

Inventor： LU GENMIN ,  PHILLIPS DAVID R ,  ANDRE PATRICK ,  SINHA UMA

IPC: C12N9/64 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/715 ,  A61K31/727 ,  A61K38/36 ,  A61K38/48 ,  A61K39/00 ,  A61K39/395 ,  A61K47/48 ,  A61P7/02 ,  A61P7/04 ,  C07H21/00 ,  C07K14/00 ,  C07K16/00 ,  C12N5/10 ,  C12P21/00

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

公开(公告)号：CA2688319A1

公开(公告)日：2008-11-13

申请号：CA2688319

申请日：2008-05-02

Applicant: PORTOLA PHARM INC

Inventor： GAO DACAO ,  ANDRE PATRICK ,  PHILLIPS DAVID R ,  STEPHENS GILLIAN

IPC: A01N37/10 ,  A61K31/19

Abstract: The present invention provides new methods of treating thrombosis and car diovascular diseases using of antithrombotic agents, as well as methods of d etermining therapeutically effective amounts of antithrombotic agents and un it dose formulations thereof.

公开(公告)号：CA2688317A1

公开(公告)日：2008-11-13

申请号：CA2688317

申请日：2008-05-02

Applicant: PORTOLA PHARM INC

Inventor： ANDRE PATRICK ,  PHILLIPS DAVID R ,  HOMCY CHARLES J

IPC: A61K31/4365 ,  A61K31/34 ,  A61K31/352 ,  A61K31/405 ,  A61K31/421 ,  A61K31/4406 ,  A61K31/616 ,  A61P7/02 ,  A61P9/00 ,  C12N9/02 ,  C12Q1/00

Abstract: The present invention provides methods and compositions useful in the tre atment or prevention of cardiovascular disorders in individuals for whom the rapy with a COX-1 enzyme inhibitor is not feasible due to sensitivity, intol erance, or resistance to the inhibitor. Additionally, the invention provides methods of treating cardiovascular disorders in an individual who is receiv ing a therapeutically effective dose of a TP modulator and is instructed or advised to avoid and/or not to take aspirin or another COX-1 inhibitor.

公开(公告)号：AU2005235289A1

公开(公告)日：2005-11-03

申请号：AU2005235289

申请日：2005-04-18

Applicant: PORTOLA PHARM INC

Inventor： ANDRE PATRICK ,  HOMCY CHARLES ,  PHILLIPS DAVID R

IPC: A61K31/4745 ,  A61F2/02 ,  A61K31/473 ,  A61K31/52

Abstract: The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.